ATHA - Athira Pharma Corp Value Adjusted for Debt and Cash
The Athira Pharma, Inc. (ATHA) price chart helps assess the value of a biotech system creating a closed-loop of regenerative therapies, where the metric stands at 4.04. The project leverages the expertise of leading neurobiologists focused on brain cell regeneration. Athira Pharma, Inc. (ATHA) is currently revising its search strategies and preclinical plans due to ambiguous results from recent tests of dementia drugs.
Athira Pharma, Inc. - analytical breakdowns and key metrics (ATHA)
Enterprise Value (EV) represents the total acquisition price of an asset, combining market capitalization and net debt. For Athira Pharma, Inc. (ATHA), the current business value including liabilities stands at 4.04. This metric reflects the company's actual financial weight regardless of its capital structure. Given the dependence on clinical trials, this indicator demonstrates the business's resilience to external cycles. Investors should utilize this metric for an objective assessment of the company's fundamental value.